“I couldn’t be prouder of the PetMedix team’s accomplishments. Tom Weaver, co-founder and CEO of PetMedix. That is the whole point of our company,” commented Dr. Zoetis’ market-leading expertise in developing, manufacturing, and commercializing innovative medicines will help PetMedix’s rich portfolio of transformative monoclonal antibodies progress more quickly towards regulatory approvals in global markets and make a real difference in the lives of pets and their owners. Through their vision and focus on the best science they were the first to launch successful mAb therapeutics to treat chronic diseases in companion animals. Zoetis was the first animal health company to appreciate the power of monoclonal antibody therapy, a technology that was created in Cambridge and has transformed human health. Zoetis is an ideal partner for us, innovation to bring new solutions to their customers is their number one focus, and this aligns 100% with our approach. “Today marks a new milestone as PetMedix joins forces with Zoetis, the world’s leading animal health pharmaceutical company. Located at the heart of Europe’s most successful biotechnology cluster, PetMedix will continue operations and act as one of Zoetis’ innovation hubs, providing a center of research excellence to harness advances in basic and translational research and drive the creation of new treatments for animal disease. In addition to successful research collaborations, PetMedix’s proprietary drug development activities have led to a promising and large portfolio of antibody drug candidates targeting areas of unmet clinical need in both chronic and terminal diseases affecting dogs and cats. Both parties have collaborated since 2022 with respect to antibody discovery. PetMedix, a leader in discovering species-specific therapeutic antibodies for pets, announced that it has been acquired by Zoetis, the world’s leading animal health company.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |